The American Journal of Managed Care

Denosumab Biosimilars Approved With Interchangeability to Address Osteoporosis, Fracture Risk

Ospomyv and Xbryk, biosimilars to Prolia and Xgeva, received FDA approval for osteoporosis and bone loss treatment. Clinical studies confirmed equivalent efficacy, safety, and pharmacokinetics between ...
Monthly Prescribing Reference

Denosumab Increases Cardiovascular Risk in Dialysis-Dependent Patients

The study included 1032 patients: 658 denosumab users and 374 oral bisphosphonate users. HealthDay News — For dialysis-dependent patients treated for osteoporosis, denosumab is associated with a ...
Seeking Alpha

Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®

BRIDGEWATER, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (AMRX) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced ...
Healio

Lower fracture, higher cardiovascular risks seen with denosumab for patients on dialysis

Please provide your email address to receive an email when new articles are posted on . Compared with oral bisphosphonate use, denosumab use was associated with a 45% lower risk for fractures among ...
The American Journal of Managed Care

FDA Approves Denosumab Biosimilars Stoboclo and Osenvelt

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...
Cure Today

FDA Approves Stoboclo and Osenvelt as Biosimilars Across Some Cancers

Stoboclo and Osenvelt, biosimilars of Prolia and Xgeva, are approved for various cancer-related bone conditions, offering cost-effective alternatives. FDA approval confirms therapeutic equivalence of ...